Turn’s mRNA-based ERA™ Platform is safe and fast

Turn Biotechnologies’ proprietary ERA™ Platform uses mRNA to deliver transcription factors to the epigenome. The platform is safe, fast, efficient and tunable.

Turn’s ERA Platform enables us to carefully control the time, duration and dosage of transcription factors to optimize the mRNA cocktail for each indication. For example, we can add or subtract specific factors, depending on the benefit they provide with specific tissue.

Then we can control reprogramming, moving the epigenome to a more youthful state one step at a time, by carefully pulsing the cell with the transcription factors. As the animation below shows, each pulse drives the epigenome to a more vigorous state, protecting the patient while steadily restoring cell functionality.